Producto añadido correctamente al carrito.

discount label
H-G^V^Y^D^G^R^E^HT^V^-OH
Ver en 3D

Biosynth logo

H-G^V^Y^D^G^R^E^HT^V^-OH

Ref. 3D-PP47563

Tamaño no definidoA consultar
Entrega estimada en Estados Unidos, el Miércoles 11 de Diciembre de 2024

Información del producto

Nombre:
H-G^V^Y^D^G^R^E^HT^V^-OH
Descripción:

Peptide H-G^V^Y^D^G^R^E^HT^V^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-G^V^Y^D^G^R^E^HT^V^-OH include the following: A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes Y Zhang , V Stroobant, V Russo, T Boon - Tissue , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-0039.2002.600503.x Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes T Ninkovic, L Kinarsky, K Engelmann, V Pisarev - Molecular , 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589008007001 New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells T Kobayashi, C Lonchay, D Colau, N Demotte - Tissue , 2003 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-0039.2003.00123.x Large-scale molecular dynamics simulations of HLA-A*0201 complexed with a tumor-specific antigenic peptide: Can the alpha3 and beta2m domains be neglected? S Wan , P Coveney , DR Flower - Journal of computational , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/jcc.20100 High-resolution structure of HLA-A∗ 0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene RC Hillig, PG Coulie , V Stroobant, W Saenger - Journal of Molecular , 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022283601948168 Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy PC Simister, EC Border , JF Vieira - for Immunotherapy of , 2022 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295655/ Theoretical Dynamics and Energetics of HLA-A2/SLYNTVATL Interaction O Olaposi, H Tsuyoshi - American Journal of Bioinformatics Research, 2015 - academia.eduhttps://www.academia.edu/download/70861651/10.5923.j.bioinformatics.20150501.01.pdf A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes MT Duffour, P Chaux, C Lurquin - European journal of , 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1521-4141(199910)29:10%3C3329::AID-IMMU3329%3E3.0.CO;2-7 A library of cancer testis specific T cell receptors for T cell receptor gene therapy MAJ de Rooij, DFG Remst, DM van der Steen - Molecular Therapy , 2023 - cell.comhttps://www.cell.com/molecular-therapy-family/oncology/fulltext/S2372-7705(22)00142-5 de, Remst, DFG, Steen, DM an der, Wouters M Rooi - K., Hagedoorn, RS, Kester, MGD , 2023 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3616927/download Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗ 02: 01 complex L Wang , M Matsumoto, Y Akahori, N Seo , K Shirakura - Molecular Therapy, 2024 - cell.comhttps://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(24)00018-2 Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based K Davari, T Holland, L Prassmayer - for Immunotherapy of , 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996660/ Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy JP Sanderson , DJ Crowley, GE Wiedermann - , 2020 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2019.1682381 A de-risking experimental framework defines the physiological interactome of TCR-based therapeutics in human tissues E Marrer-Berger, A Nicastri , A Augustin, V Pulko - 2022 - researchsquare.comhttps://www.researchsquare.com/article/rs-1828302/latest

Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Biosynth
Almacenamiento de larga duración:
Notas:

Propiedades químicas

MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:

Información de peligrosidad

Número UN:
Cantidad exceptuada (EQ):
Clase:
Frases H:
Frases P:
Prohibido volar:
Información de peligrosidad:
Grupo de empaquetado:
Cantidad limitada (LQ):

Consulta técnica sobre: 3D-PP47563 H-G^V^Y^D^G^R^E^HT^V^-OH

Use el carrito para solicitar presupuestos o pedidos

Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.

* Campos obligatorios
¡Bienvenido a CymitQuimica!Utilizamos cookies para mejorar su visita. No incluimos publicidad.

Consulte nuestra Política de Cookies para obtener más información o ajuste sus preferencias en "Configurar".